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Catheter-based Intramyocardial 
Injection of FGF1 or NRG1-loaded 
MPs Improves Cardiac Function in 
a Preclinical Model of Ischemia-
Reperfusion
Elisa Garbayo1,2,*, Juan José Gavira2,3,*, Manuel Garcia de Yebenes2,3, Beatriz Pelacho2,3, 
Gloria Abizanda2,3, Hugo Lana1,2, María José Blanco-Prieto1,2,† & Felipe Prosper2,3,†
Cardiovascular protein therapeutics such as neuregulin (NRG1) and acidic-fibroblast growth factor 
(FGF1) requires new formulation strategies that allow for sustained bioavailability of the drug in the 
infarcted myocardium. However, there is no FDA-approved injectable protein delivery platform due 
to translational concerns about biomaterial administration through cardiac catheters. We therefore 
sought to evaluate the efficacy of percutaneous intramyocardial injection of poly(lactic-co-glycolic 
acid) microparticles (MPs) loaded with NRG1 and FGF1 using the NOGA MYOSTAR injection catheter 
in a porcine model of ischemia-reperfusion. NRG1- and FGF1-loaded MPs were prepared using a 
multiple emulsion solvent-evaporation technique. Infarcted pigs were treated one week after ischemia-
reperfusion with MPs containing NRG1, FGF1 or non-loaded MPs delivered via clinically-translatable 
percutaneous transendocardial-injection. Three months post-treatment, echocardiography indicated 
a significant improvement in systolic and diastolic cardiac function. Moreover, improvement in bipolar 
voltage and decrease in transmural infarct progression was demonstrated by electromechanical 
NOGA-mapping. Functional benefit was associated with an increase in myocardial vascularization 
and remodeling. These findings in a large animal model of ischemia-reperfusion demonstrate the 
feasibility and efficacy of using MPs as a delivery system for growth factors and provide strong evidence 
to move forward with clinical studies using therapeutic proteins combined with catheter-compatible 
biomaterials.
Heart failure remains the leading global cause of death1. Growing evidence indicates that growth factor ther-
apy is a promising approach to treat myocardial infarction (MI)2,3. Therapeutic proteins, including neuregulin-1 
(NRG1), acidic-fibroblast growth factor (FGF1), vascular endothelial growth factor and erythropoietin have been 
implicated in the mechanism of cardiac repair after MI3–6. However, despite several compelling preclinical and 
initial clinical studies7–9, double-blinded clinical trials with large cohorts of patients have failed to validate the 
efficacy of protein therapy in MI patients10–14. Limited stability and rapid degradation after administration are 
critical challenges that may hamper the translation of therapeutic proteins into widespread clinical use. Proteins 
require new formulation strategies that allow for sustained bioavailability of the protein locally in the infarcted 
myocardium. The combination of injectable biomaterials with growth factors represents a key strategy able to 
address shortcomings of protein therapy for cardiac regeneration. However, although extensive research has been 
performed in this area, there is no FDA-approved injectable protein delivery platform for MI treatment at present, 
due to translational concerns related to biomaterial administration through cardiac catheters.
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Different biomaterials have been investigated for cardiac regeneration15–17. Of particular interest in the field of 
regenerative medicine are synthetic polymers like the polyesters poly(lactic-co-glycolic acid) (PLGA), which have 
reached FDA approval for clinical application in tissue repair18 with a demonstrated track record as vehicles for 
protein delivery. Significant research has been carried out on the development of bioresorbable stent scaffolds19–21 
and drug delivery systems22,23 using PLGA polymer for heart tissue engineering applications. Interestingly, PLGA 
can be shaped/processed into delivery systems like microparticles (MPs), which can be injected through cardiac 
catheters allowing controlled local delivery of proteins directly in relevant areas of the heart24–26. Recently, we 
demonstrated the benefit of incorporating NRG1 and FGF1 within bioresorbable PLGA-MPs that can generate 
sustained growth factor levels in the ischemic myocardium in a rat MI model, leading to induction of tissue 
revascularization, activation of endogenous regeneration and eventually improving heart function26. PLGA-MPs 
were prepared by a multiple emulsion solvent-evaporation technique using the Total Recirculation One-Machine 
System (TROMS). This technology produces very homogeneous batches on a semi-industrial scale, which is of 
great interest for future industrial manufacturing.
The goal of this study was to scale up our previous studies26 into a clinically-relevant preclinical porcine model 
of ischemia-reperfusion in order to demonstrate the feasibility and efficacy of percutaneous intramyocardial 
delivery of PLGA-MPs loaded with NRG1 and FGF1 using the NOGA MYOSTAR injection catheter. Notably, 
the percutaneous delivery of growth factor loaded MPs through the catheter-based NOGA navigating system 
achieved a sustained growth factor release in the MI region and a significant recovery of cardiac function associ-
ated with therapeutic neovascularization and remodeling.
Results
Preparation and characterization of injectable growth factor loaded MPs. FGF1 and NRG1 were 
successfully encapsulated in PLGA MPs prepared by multiple emulsion solvent evaporation technique using the 
TROMS. The mean particle size measured by laser diffractometry was 7.2 ± 1.9 μ m, with a range of particle size 
from 0.5 to 35 μ m, which is compatible with an intramyocardial administration using the 27 G NOGA cathe-
ter27,28 (Fig. 1A). Scanning electron microscopy (SEM) analysis showed that PLGA MPs had a spherical shape 
Figure 1. Characterization of injectable MPs loaded with FGF1 and NRG1. (A) MP size distribution.  
(B) Scanning electron microscopy images showing the morphology of MPs. (C) Encapsulation efficiency. 
Western blot bands corresponding to FGF1/NRG1 standard curve and FGF1/NRG1 encapsulated in MPs 
(D) In vitro effect of MP-released cytokines on heart-derived cells. H9c2 cells were cultured in the presence 
of either MP-released or free FGF1 and NRG1. Values are the mean fold-increase in cell number over a 72-h 
period ± SEM from three independent experiments. (One–way ANOVA with a post-hoc Tukey’s multiple 
comparison test; **p < 0.01 ***p < 0.001).
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with a smooth surface (Fig. 1B). One purpose of the study was to prepare MPs loaded with at least 250 μ g/100 mg 
polymer to allow dose scale up according to body weight in transition from small to large animal models of 
MI. To this aim, the amount of therapeutic protein loaded into MPs (100 mg) was therefore increased to 300 μ 
g. Growth factors were efficiently encapsulated, reaching values of 84 ± 15.5% for FGF1 and 83.5 ± 13.2% for 
NRG1 determined by western blot (Fig. 1C). The total amount of loaded FGF1 and NRG1 was 252.1 ± 46.5 and 
250.5 ± 39.7 μ g/100 mg polymer respectively, suitable for in vivo studies in minipigs. Both formulations showed 
low initial protein burst release in vitro (i.e. ~12.6% of NRG1 and ~10% of FGF1 were released during the first 
15 hours) as previously reported by our group for this kind of formulation26. The bioactivity of the cytokines 
released from the MPs was evaluated by the induction of H9c2 cardiomyocyte proliferation. The rate of cell pro-
liferation was significantly increased 1.3 and 2.1 fold when stimulated with FGF1 and NRG1 released from MPs 
respectively (p < 0.001 vs. control). Proliferation rates of free-cytokine treated-cells were similar to those obtained 
with the cytokines released by MPs, indicating that both cytokines remained bioactive after microencapsulation 
and release, and demonstrating that the developed delivery system allowed the maintenance of protein stability 
during manufacture and release (Fig. 1D).
FGF1 and NRG1-MPs improves cardiac function after ischemia-reperfusion in pigs. We 
then tested our hypothesis that injection of FGF1 or NRG-1 MPs would improve cardiac function after 
ischemia-reperfusion in a large animal model of MI. Seven days after ischemia-reperfusion animals were 
divided in three groups and treated with transendocardial injections of FGF1-MPs (n = 6), NRG1-MPs (n = 5) 
or control-MPs (non-loaded) (n = 6) using the Myostar catheter. The mean number of injections per animal was 
27.7 ± 0.9, 27 ± 1.9 and 27.3 ± 3.5 respectively. The amount of MPs was 79.3 mg, 79.8 mg and 79.8 mg respec-
tively. The volume administered in each injection was 0.3 mL. MP suspension (± 10 mg MPs/mL) showed good 
injectability through the NOGA-guided MyoStar catheter equipped with a 27 G needle. Particle aggregation, 
catheter clogging or needle blockage during the administration of the MP suspension was not observed. During 
transendocardial injection, 2 animals experienced ventricular tachycardia and required cardioversion. No other 
side effects (arrhythmias or other cardiac events) were documented before or after the procedure.
Temporal coronary occlusion followed by reperfusion caused a marked decrease in fractional shortening (FS) 
at day 7 (38.6 ± 3.8% at baseline versus 19.4 ± 3.5 before implant; p < 0.0001), which did not significantly differ 
among groups (p = 0.56). Measurement of cardiac function was evaluated 3 months after NOGA-guided transen-
docardial MP injection. While no significant changes were found in the FS in the control group 3 months after 
implant (Control-MPs: 19.1 ± 2.1), transplantation of NRG1-MPs or FGF1-MPs was associated with a statistically 
significant benefit in cardiac contractility as shown by higher FS (FGF1-MPs: 28.2 ± 6.1, NRG1-MPs: 27.9 ± 6.1) 
(Fig. 2).
Additionally, FGF1-MP and NRG1-MP injection prevented the deterioration of ventricle geometry, as indi-
cated by the decrease in end-systolic and end-diastolic diameters (Table 1) in comparison with control animals, 
where a progressive worsening of the ventricular diameters was observed. Altogether, these results demonstrate a 
beneficial effect of the MPs, inducing adequate remodeling of the heart.
Electromechanical NOGA data were collected pre-injection and before sacrifice in control-MPs (n = 3), 
NRG1-MPs (n = 5) and FGF1-MPs (n = 4) treated animals. Bipolar voltages were analyzed in 9 bulls-eye seg-
ments used to calculate the change in tissue viability and transmural infarct dimensions over the course of the 
experiment, as this method has been demonstrated to accurately predict the transmural extent of myocardial 
infarction29. Bipolar voltage measurements at time of injection and after 3 months revealed an overall reduction 
of − 12.5 ± 9.9% from baseline values in control pigs and a significant increase in NRG1-MPs (+ 19.8 ± 12.3%) 
and FGF1-MPs (+ 10.7 ± 5.2%) treated animals (p < 0.05) (Fig. 3A).
Moreover, infarct areas were extracted from NOGA maps in order to evaluate the effect of MP injection on 
the extent of the infarcted area. Areas with bipolar voltage values lower than 0.8 mV were considered transmu-
ral scar, as previously described30. In control-MP treated animals we observed an average fractional increase of 
2.1 ± 0.5 indicating a doubling of the transmural infarct areas. However, in animals treated with NRG1-MPs and 
Figure 2. Echocardiographic data shows improvement in systolic function after treatment with FGF1 and 
NRG1 loaded MPs. FS was assessed by echocardiography in minipigs 3 months after NRG1-MPs or FGF1-MPs 
injection. Data are expressed as mean ± SEM (One–way ANOVA with a post-hoc Tukey’s multiple comparison 
test; **p  < 0.01).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:25932 | DOI: 10.1038/srep25932
Baseline Implant Sacrificed P
FS
 Control-MPs 38.4 (4.4) 19.5 (3.2)*** 19.1 (2.1) 0.51
 NRG1-MPs 36.8 (4.1) 20.6 (3.2)*** 27.9 (6.1) 0.025
 FGF1-MPs 40.1 (2.8) 18.8 (4.2)*** 28.2 (6.1) 0.001
EDD
 Control-MPs 4.60 (0.73) 5.21 (0.71) 5.31 (0.62) 0.71
 NRG1-MPs 4.54 (0.75) 5.12 (0.56) 4.84 (0.58) 0.52
 FGF1-MPs 4.09 (0.45) 4.85 (0.73) 4.72 (0.77) 0.61
ESD
 Control-MPs 2.75 (0.71) 3.97 (0.88) 4.05 (0.78) 0.80
 NRG1-MPs 3.07 (0.59) 4.04 (0.46)** 3.91 (0.34) 0.66
 FGF1-MPs 2.48 (4.09) 4.09 (0.72)** 3.29 (0.55) 0.058
Table 1.  Echocardiography data from porcine MI study. Pre-implant measurements were taken 7 days after 
ischemia-reperfusion injury and pre-euthanasia measurements 3 months after injection. Data are means (SD). 
**P < 0.01 baseline versus pre-implant, ***P < 0.001 baseline versus implant; EDD: end diastolic diameter, ESD: 
end systolic diameter, FGF1, acidic fibroblast growth factor, FS: fractional shortening, MPs: microparticles, 
NRG1: neuregulin.
Figure 3. Transcatheter based, NOGA mapping guided intramyocardial injection of growth factor loaded-
MPs in pigs. (A) Bipolar changes three months after implantation in comparison with baseline levels.  
(B) Infarct expansion calculated as the increase in the area with bipolar voltage values lower than 0.8 mV 
3 months after treatment. (C) Bipolar changes three months after injection comparing segments in which 
particles were directly injected or non-injected. Data in A, B and C are means ± SEM. (One–way ANOVA  
with a post-hoc Tukey’s multiple comparison test; *p < 0.05).
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FGF1-MPs the infarct size increased only marginally (1.2 ± 0.1 and 1.2 ± 0.3) (Fig. 3B). Differences between 
control-MP treated animals and NRG1-MP or FGF1-MP treated pigs were statistically significant (p < 0.05). 
When injected and non-injected segments were analyzed separately and compared between control and animals 
treated with growth factors loaded MPs, changes in bipolar voltages in non-injected segments showed the same 
pattern as changes observed when only injected segments were analyzed (Fig. 3C), suggesting growth factor 
diffusion to other heart areas. Representative bipolar map changes of a NRG1-MP treated animal at baseline 
and before sacrifice are illustrated in Fig. 4. Collectively, these results indicate that the injection of NRG1 and 
FGF1-MPs improves cardiac function after MI.
FGF1 and NRG1-MPs promote heart tissue revascularization. No adverse cellular reactions or signs 
suggestive of localized toxicity from the MPs were observed during the histological evaluation of the hearts. 
We then determined the effect of MPs injection on vasculogenesis and analyzed whether functional efficacy 
was accompanied by increased revascularization. Three months after treatment, a significant increase in vas-
cularization was detected in the ischemic zone at the arteriolar/arteries level (Fig. 5A). The α -smooth muscle 
actin (α SMA)+ vessel area was significantly increased after the administration of any of the cytokine-loaded MPs 
in comparison with the control-MPs (Control-MPs: 4838.56 ± 655.6 μ m2, NRG1-MPs: 7993.76 ± 675.72 μ m2; 
P < 0.01, FGF1-MPs: 7380.91 ± 387.73 μ m2; P < 0.05) (Fig. 5B). Additionally, the α SMA+ vessel density was sig-
nificantly greater in animals treated with FGF1-MPs or NRG1-MPs: (Control-MPs: 54.92 ± 3.32 vessels/mm2, 
NRG1-MPs: 113.22 ± 15.46 vessels/mm2; P < 0.01, FGF1-MPs: 121.15 ± 9.71 vessels/mm2; P < 0.001) (Fig. 5C). 
Thus, transplantation of FGF1 and NRG1-MPs promoted heart tissue vascularization. Furthermore, a significant 
positive correlation between FS and vasculogenesis was observed (R = 0.734; p = 0.001), suggesting that cytokine 
loaded MPs may contribute to improvement in cardiac function by increasing the vasculogenesis in the infarct 
tissue (Fig. 5D).
NRG1-MPs reverse cardiac fibrosis. Finally, to ascertain the effect of growth factor-loaded MPs in car-
diac fibrosis and analyze whether cardiac function improvement was associated with a lower degree of fibrosis, 
we quantified the total collagen content in animals receiving NRG1- or FGF1-MPs (Fig. 6). It was observed that 
NRG1-MPs reversed cardiac fibrosis in the infarcted area (Fig. 6A). Quantification of collagen deposition shows 
that the degree of fibrosis in the infarct zone was significantly diminished in the animals treated with NRG1-MPs 
in comparison with the control group three months after treatment. On the other hand, a significant effect on 
tissue remodeling was not detected in animals treated with FGF1-MPs (% Fibrosis: Control-MPs: 40.9 ± 2.8%, 
NRG1-MPs: 26.2 ± 4.5%; P < 0.05, FGF1-MPs: 41.8 ± 6.6%,) (Fig. 6B). Notably, we observed a significant neg-
ative correlation between FS and the degree of fibrosis between NRG1-MP and Control-MP treated groups 
(R = − 0.6052; p = 0.0485) suggesting that NRG1-MP may improve cardiac function by attenuating cardiac fibro-
sis in the ischemic area.
Discussion
The present study demonstrates the feasibility and efficacy of MPs as an injectable protein delivery biomaterial for 
treating MI through minimally invasive approaches in a clinically relevant model of ischemia-reperfusion. Our 
Figure 4. Representative bipolar area NOGA maps taken at time of injection (A) and euthanasia (B) of a 
NRG1-MP treated animal. The mapping points are shown by white dots. Dark dots in A, represent the injection 
sites.
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findings further show that FGF1 or NRG1 administration via MPs in minipigs has therapeutic effects, supporting 
the role of this strategy for administration of therapeutic proteins to repair injured heart tissue.
Cardiac biomaterials are a promising approach for MI treatment31. Advanced delivery methods combining 
biomaterials with therapeutic growth factors are needed to maximize protein therapeutic potential, reduce del-
eterious effects and aid clinical translation2. Among drug delivery systems, MPs are able to provide sustained 
protein release and a decrease in drug dosage, holding great promise in cardiac tissue engineering. These drug 
delivery systems can be injected through cardiac catheters in a minimally invasive manner, which is extremely 
important for a faster clinical translation. Thus, examining MP safety and efficacy is critical for the development 
of new vehicle that can be used in combination with protein-based approaches for MI treatment. In this regard, 
we previously characterized the cellular and molecular mechanism of FGF1 and NRG1-MPs as well as its efficacy 
on small animal models of acute MI26. Our previous work indicated that treatment with FGF1 and NRG1-MPs in 
a rat model of acute MI induced an improvement in cardiac function which was associated with cardiomyocyte 
proliferation, progenitor cell recruitment, increased angiogenesis and decreased fibrosis26. Based on these results, 
in the current study we used a clinically relevant large-animal model of MI to examine the translational potential 
of this therapy. In the current paper, we not only confirm our previous results, demonstrating the therapeutic 
efficacy of combining MP-based delivery systems with FGF1 or NRG1 in a pig MI model24–26, but also further 
demonstrate for the first time the feasibility of MPs as an injectable material for treating MI through minimally 
invasive approaches, proving its potential for clinical application.
Among the strategies aimed at improving protein therapy, the local administration of growth factors within a 
biomaterial-based delivery system represents an attractive therapeutic strategy. Numerous studies have already 
shown that injectable protein-releasing biomaterials are able to improve cardiac function in small animal models 
of MI15. Among them, only hydrogels and nanofibers co-delivered with therapeutic proteins have demonstrated 
myocardial repair and regeneration in large animal models of MI32–34. However, most of these strategies were 
implanted using an open surgical method, since very few materials can be administered using minimally inva-
sive procedures. In addition, technical difficulties related to hydrogel injection using existing catheter technol-
ogy, such as rapid gelation during administration or needle blockage due to high hydrogel viscosity, have been 
reported35. In other cases, hydrogels require mixing and incorporation of crosslinking agents prior to injection, 
which hinders their administration via cardiac catheters. Regarding peptide nanofibers, they need to be opti-
mized to be delivered via catheter to facilitate their translation to clinical practice. Alternatively, as shown in 
our study, PLGA-MPs may be superior to other drug delivery devices such as cardiac patches, membranes, or 
nanofibers owing to their injectability through a NOGA guided catheter, as well as their potential for targeting 
different areas of the heart. Here we show that cytokine-loaded MPs preserved cardiac function post-MI, and also 
demonstrate that MPs are deliverable via cardiac catheter. MPs were successfully injected in the porcine infarcted 
Figure 5. FGF1 and NRG1 released from MPs in the ischemic miocardium lead to angiogenic effects. 
(A) Representative images showing the infarcted/peri-infarcted area three months after treatment stained 
with antibodies against blood vessels (α -SMA+) and nuclei (DAPI) in sections of each group of animals. 
Quantification of α -SMA total area (B) and vessel density (C) in infarcted and peri-infarcted zones 3 months 
after growth factor loaded MP or control-MP injection. Data are means ± SEM. (One–way ANOVA with a post-
hoc Tukey’s multiple comparison test; *p < 0.05 **p < 0.01 ***p < 0.001). (D) Correlation between functional 
echocardiographic parameters and α -SMA vessel density (Pearson Correlation analysis R =  0.734; p =  0.001).
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myocardium without clogging the catheter or blocking the needle, which shows that this protein delivery bioma-
terial is clinically relevant for percutaneous injection in the heart.
As demonstrated in the present study, a crucial aspect of biomaterial clinical translation is the delivery 
method. NOGA technology has several advantages, as it allows for guided, direct intramyocardial injection, 
which increases biomaterial retention and does not require access to the coronary vessels, reducing the risk of 
embolization36. In our study, no serious adverse events were observed during MP administration, which might 
indicate the safety of this delivery method. The mapping technology also facilitates the distinction between viable, 
non-viable, stunned or hibernating myocardium, facilitating targeting to ischemic and peri-ischemic myocardial 
regions in patients with chronic myocardial ischemia, reducing the likelihood of systemic toxicity of the injected 
substance due to off-target effects. In the present study, cardiac function was significantly improved after treat-
ment with growth factor loaded MPs as measured by bipolar electrical changes, a proven measurement of infarct 
transmurality29, which was associated with improved contractibility, adequate heart remodeling and increased 
vascular density. The lack of differences in unipolar voltage potential between the different groups is not sur-
prising, as this parameter might be beneficial for identifying subendocardial scars, but does not determine the 
electrical status of the transmural myocardium37.
Many growth factors have been explored for ischemic heart disease treatment based on their capacity to 
induce angiogenesis, recruit stem and progenitor cells, or contribute to cardiomyocyte proliferation2,3. The deci-
sion to encapsulate NRG1 was based on previous studies implicating this cytokine in cardiac development, but 
also in the myocardium physiology, from angiogenesis induction to cardiomyocyte proliferation and cardiac 
progenitor cell recruitment4,6,38. On the other hand, from the large family of fibroblast growth factors, we focused 
on FGF1 on the basis of its capacity to stimulate angiogenesis and cardiomyocyte mitosis, and to restore cardiac 
function after MI39. Both PLGA-MP and cytokine dose represent an important aspect for this therapy to be suc-
cessful. Based on studies from our group that have demonstrated in a rat MI model that PLGA particles remain 
in the heart 3 months after direct intramyocardial injection40 and that the bioactive protein is released in a con-
trolled manner at least for twelve weeks41, a dose of 200 μ g of cytokine per animal was used. We have previously 
demonstrated that a short cytokine stimulus, if it is not sustained, is not able to reduce infarct size or to induce 
therapeutic angiogenesis in a rat MI model, owing to the short half-life of proteins24. In support of this, in many 
of the studies involving the development of drug delivery systems to increase the release and the half-life of the 
growth factor, controls with the free cytokine have led to lack of efficacy42,43. What is more, the use of free growth 
factors in MI phase II clinical trials has been associated with limited success10–14. For all these reasons, the injec-
tion of the free proteins was not examined in the present work. Here, we show that the transendocardial injection 
of FGF1 or NRG1-MPs post-MI in minipigs induces heart tissue revascularization, proving that FGF1/NRG1 are 
Figure 6. Effect of FGF1 and NRG1-MP on cardiac fibrosis. (A) Representative images showing the 
infarcted area three months after treatment stained with Sirius Red in sections of each group of animals. 
(B) Quantification of collagen deposition in the infarcted zones 3 months after growth factor loaded MP or 
control-MP injection. Data are means ± SEM. (Kolmogorov-Smirnov test showed no Gaussian distribution 
and the non-parametric Kruskal Wallis test was used; *p < 0.05). (C) Correlation between functional 
echocardiographic parameters and % fibrosis between MRG1-MP and Control-MP (Pearson Correlation 
analysis R = − 0.6052; p = 0.0485).
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very potent angiogenic factors and confirming our previous work on a rat MI model26. Moreover, the positive 
correlation between left ventricular ejection fraction (LVEF) and vasculogenesis indicate that cytokine loaded 
MPs may improve heart function through enhancement of angiogenesis in the core infarct tissue. Similarly, most 
of the examined biomaterials that brought about an improvement in cardiac function displayed neoangiogene-
sis33,44,45. The sustained release of NRG1 or FGF1 from MPs may provide a prolonged and effective angiogenic 
stimulus to the ischemic heart, something that was not achieved in clinical trials with pro-angiogenic factors, and 
which may explain the disappointing results obtained46. Thus, the controlled delivery of FGF1 and NRG1 from 
MPs may initiate healing at the site of the injection, increasing new vessel formation, restoring the blood supply to 
the infarcted area, and in consequence, inducing an adequate heart remodeling process. Additionally, NRG1-MPs 
were also able to reverse cardiac fibrosis, thus affording functional improvement, as previously reported by our 
group and by others26,47,48. Our data might also suggest that the efficacy of FGF1-MPs is not directly associated 
with prevention of fibrosis. It was shown previously that FGFs play distinct roles in cardiac remodeling49. While 
FGF16 and FGF21 may prevent cardiac hypertrophy and fibrosis, FGF2 and FGF23 display the opposite effect49. 
However, the role of FGF1 on cardiac fibrosis is less known. Based on our findings, we speculate that the improve-
ment in cardiac function observed in FGF1-MP treated minipigs was not mediated by decreased fibrosis, but 
rather by the potent angiogenic effect of FGF1.
Limited studies have investigated the impact of biomaterials on cardiac electrophysiology, a concern raised by 
stem cell injection50. In our study, MPs were safely injected without inducing arrhythmia. The small size of MPs 
and the spread of the material through the tissue are unlikely to alter cardiac electrophysiology. These results are 
in agreement with recent experiments by Singelyn et al.51, Seif-Naraghi et al.52 and Lin et al.53 reporting that both 
the injection of hydrogels derived from decellularized ventricular extracellular matrix and peptide nanofibers do 
not lead to induced arrhythmogenesis. Biomaterial location and distribution in the viable tissue might be also 
an important factor which determines the production of arrhythmias, and this should be further investigated.
Finally, from a translational perspective, the clinical development of these protein delivery MPs should be rel-
atively straightforward since: 1) PLGA has already been approved for clinical use, 2) the MP production method 
is easily reproducible and applicable on a semi-industrial scale and 3) implementation of GMP conditions, homo-
geneity between batches and the possibility to reduce contamination are facilitated using TROMS technique since 
human intervention is minimized during MP production.
In summary, the findings of this work may translate into an improved MI therapeutic strategy with the poten-
tial to improve life expectancy and quality of life in patients with MI, and to reduce costs for the healthcare 
system.
Conclusion
These data provide compelling evidence that the percutaneous intramyocardial injection of MPs loaded with 
FGF1 or NRG1 is clinically feasible and has a therapeutic effect in a large animal model of MI, indicating that 
catheter delivery of MPs might pave the way towards clinical translation of cardiac regenerative medicine for MI.
Methods
Injectable growth factor-loaded PLGA MPs preparation and characterization. FGF1 and NRG1 
were separately encapsulated into PLGA MPs through a multiple emulsion solvent-evaporation method using 
the TROMS26. Briefly, 100 mg of PLGA dissolved in 4 mL of dichloromethane/acetone was injected into the inner 
aqueous phase containing 300 μ g of growth factor, 5 mg of human serum albumin (HSA) (Sigma-Aldrich), and 
5 μ l of poly ethylene glycol 400 (PEG 400) dissolved in 200 μ l of phosphate-buffered saline. The inner emulsion 
was recirculated through the system to become homogenous and injected into the outer aqueous phase composed 
of 20 mL of 0.5% w/v polyvinyl alcohol (PVA) to obtain the multiple emulsion. After solvent evaporation and 
polymer precipitation, particles were formed. MPs were washed and lyophilized without cryoprotective agents. 
Non-loaded MPs, abbreviated control-MPs, were prepared similarly to loaded ones, but without growth factors. 
MPs were characterized as previously described26. Particle size and size distribution were measured by laser dif-
fractometry using a Mastersizer26. Particle morphology was characterized by SEM. The amount of growth factors 
encapsulated in the MPs was determined by dissolving 5 mg of lyophilized loaded MPs in 1 mL of dimethyl sul-
foxide (DMSO) followed by quantification using western blot assay. SDS-PAGE was performed onto 12% poly-
acrylamide gels and after electrophoresis the proteins were transferred onto nitrocellulose membranes. After 1 h 
blocking with 5% nonfat dried milk in Tris-buffered saline (TBS) plus 0.05% Tween 20, nitrocellulose sheets were 
incubated overnight at 4 °C with primary antibodies against FGF1 (Abcam Ab-9588 diluted 1:2000) or NRG1 
(Santa Cruz SC-1793 diluted 1:50). The binding of primary antibodies was performed by incubating membranes 
with horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (diluted 1:2000). Immunoreactive 
bands were, after several washes, visualized using LumiLight Plus western blotting substrate (Roche Diagnostics). 
Quantitative analysis of MP-extracted growth factor bands was performed by densitometry using ImageQuant 
software. Sample values were quantified using a standard curve. For the in vitro release studies, MPs (1 mg, n = 3) 
were resuspended by vortexing in 0.5 ml of PBS, pH 7.4 containing 0.1% bovine serum albumin and 0.02% 
w/w sodium azide. Incubation took place in rotating vials at 37 °C. After 15 hours, samples were centrifuged at 
25,000 × g, for 15 min and the amount of drug released was determined by western blot, as described above. The 
bioactivity of FGF1 and NRG1 released from the MP during the first 15 hours was evaluated in vitro by deter-
mining H9c2 cardiomyocyte proliferative capacity following growth factor treatment. H9c2 cells obtained from 
embryonic BD1X rat heart tissue were cultured in DMEM medium supplemented with 10% foetal bovine serum 
(FBS), 1% glutamine, and 1% penicillin/streptomycin at 37 °C under 5% CO2/95% air. Cells were sub-cultured 
when 60% confluence was achieved. Routine testing confirmed that H9c2 cells were free of mycoplasma during 
the entire study period. In order to quantify cell proliferation after growth factor stimulation, cells were seeded in 
96-well tissue culture plates at a density of 2 × 103 cells/well. After 24 h, medium was removed and H9c2 cells were 
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incubated with 150 ng/mL of growth factor released from MPs over 15 h, which had previously been quantified 
by western blot, with 150 ng/mL of free growth factors or medium alone as control. Culture medium supplemen-
tation was modified for these experiments by reducing the FBS to 5% in the culture medium. Treatments were 
removed every day, and fresh treatment was added to the cells. After 3 days of treatments, the number of viable 
cells was determined by MTT assay. The experiment was replicated three times.
Myocardial infarction porcine model. Animal experiments were approved by the Institutional Animal 
Care and Use Committee of the University of Navarra and performed according to the requirements demanded 
by the EU legislation. Figure 7 shows the experimental design.
A total of 17 Göttingen minipigs (8 males and 9 females, age between 12 and 24 months at entry in the study, 
60–80 Kg) were procured from our GLP accredited breeding center at the University of Navarra and enrolled in 
the study. MI (ischemia-reperfusion) was induced as previously described44,54,55. A 7-Fr coronary artery-guiding 
catheter was placed within the ostium under fluoroscopic guidance using a mobile C-arm (Powermobil, Siemens) 
MI was produced by occluding the left anterior descending coronary artery with a balloon catheter 2.5 just below 
the second diagonal branch. Temporary and complete occlusion was performed by balloon dilatation (8 atm) 
and maintained for 120 min, followed by reperfusion, as demonstrated by coronary angiography and ST segment 
elevation and reversion in the electrocardiogram.
Echocardiographic assessment. Transthoracic two-dimensional echocardiography was assessed using 
a Sonos 5500 ultrasound system (Philips) and a 3 MHz linear array transducer. Left ventricular remodeling was 
determined by measuring end systolic and end diastolic volumes and diameters, according to the American 
Society of Echocardiography. Diastolic function was assessed by mitral filling pulse doppler and mitral annulus 
tissue doppler. FS was determined according to Teicholz56 in parasternal short axis, due to the unreliability of the 
4-camera approach in swine57,58. Electrocardiogram and echocardiograph measures were taken at different points 
(baseline, pre-implant and sacrifice) by two investigators blinded to the type of treatment.
NOGA-guided catheter delivery of growth factor-loaded MPs. Only animals in which a region of 
MI could be detected by echocardiography and a significant reduction in FS (more than 20% reduction from 
baseline) were included in the study. Thus, 17 minipigs were implanted with growth factor-loaded MPs using 
a NOGA-guided MyoStar catheter for intra-myocardial transplantation by an investigator blinded to the type 
of treatment seven days post-MI. The animals were randomly assigned to each group. Prior to injection, a 3D 
NOGA mapping was created to generate a detailed 3D electromechanical map of the left ventricle that was used 
to guide injection. The injection was performed through a 27-gauge retractable needle, following protocols com-
monly used for cellular delivery59,60. A 1 mL Luer lock syringe was loaded with MPs dispersed in sterile aqueous 
medium (carboxymethylcellulose, polysorbate 80 and mannitol in PBS) and attached to the catheter for injection. 
The NOGA map was used to identify injection sites. Each minipig received 200 μ g of NRG1 or FGF1 in 30 injec-
tions (300 μ l/per injection) given in the border zone of the infarcted myocardium. Heart electrical mapping was 
performed in 12 animals before sacrifice (3 months post-implantation).
Histological processing and immunostaining. After sacrifice, hearts were fixed, paraffin embedded and 
then sectioned for histology. All histology sections were immunostained and analyzed in a blinded manner. MI 
location was visually assessed. Sampling of tissues consisted of scar surrounded by a ring of viable myocardium. 
Figure 7. Schematic study design. Adult pigs underwent MI induction by coronary artery occlusion followed 
by reperfusion. One week later surviving animals underwent electrical mapping followed by intramyocardially 
injection of control-MPs, NRG1-MPs and FGF1-MPs using a NOGA catheter. Three months later heart 
electromapping was assessed before sacrifice.
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Vasculogenesis was evaluated by quantifying the number and area occupied by smooth muscle-covered vessels in 
the infarct and peri-infarct areas using an anti-α SMA antibody coupled to Cy3 (C6198, Sigma, Madrid, Spain). 
A minimum of 40 sections per animal were analyzed. The degree of fibrosis was determined by quantification 
of collagen deposition stained by Sirius Red staining of serial sections. Briefly, sections were deparaffinized and 
immersed in 0.1% Fast Red (Sigma, Madrid, Spain) in a saturated solution of picric acid, for 90 minutes, dif-
ferentiated 2 minutes in hydrochloride acid (Sigma, Madrid, Spain) 0.01 N, dehydrated and mounted in DPX. 
Microphotographs were obtained on a Nikon Eclipse E800 microscope and analyzed with a computerized system 
(Axiovision 4.6, Zeiss, Germany).
Statistical analysis. Data are presented as mean ± SEM. Normality was tested with the Shapiro–Wilk and 
Kolmogorov–Smirnov normality tests. For normal distributions, the One-Way ANOVA test was used for com-
parisons among the three treatment groups. The Kruskal–Wallis tests were used for non-normal distributions. 
Linear regression analysis was performed using Pearson’s correlation coefficients. Statistical analysis was per-
formed using GraphPad Prism 5 software. Statistical significance was determined by P values < 0.05.
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